154 related articles for article (PubMed ID: 33610652)
21. Physician social networks and variation in prostate cancer treatment in three cities.
Pollack CE; Weissman G; Bekelman J; Liao K; Armstrong K
Health Serv Res; 2012 Feb; 47(1 Pt 2):380-403. PubMed ID: 22092259
[TBL] [Abstract][Full Text] [Related]
22. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF
BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
[TBL] [Abstract][Full Text] [Related]
23. Practice Competition and Treatment of Newly Diagnosed Prostate Cancer.
Maganty A; Hollenbeck BK; Kaufman SR; Oerline MK; Lai LY; Caram MEV; Shahinian VB
Urology; 2023 Jul; 177():95-102. PubMed ID: 37146728
[TBL] [Abstract][Full Text] [Related]
24. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA
J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393
[TBL] [Abstract][Full Text] [Related]
25. 2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction.
O'Leary MP; Baum NH; Blizzard R; Blute ML; Cooper TP; Dineen MK; Fenninger RB; Gee WF; Gormley EA; Ignatoff JM; Nachtsheim DA; Painter MR; Thomas R; Wei JT;
J Urol; 2002 Aug; 168(2):649-52. PubMed ID: 12131336
[TBL] [Abstract][Full Text] [Related]
26. Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance.
Zambrano IA; Hwang S; Basak R; Spratte BN; Filson CP; Jacobs BL; Tan HJ
Urol Oncol; 2023 Sep; 41(9):388.e1-388.e8. PubMed ID: 37286404
[TBL] [Abstract][Full Text] [Related]
27. Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?
Kishan AU; Duchesne G; Wang PC; Rwigema JM; Saigal C; Rettig M; Steinberg ML; King CR
Am J Clin Oncol; 2018 Jun; 41(6):549-557. PubMed ID: 27560157
[TBL] [Abstract][Full Text] [Related]
28. [Implementation of the S3 prostate cancer guideline in daily clinical practice: results of a survey among urologists].
Fröhner M; Khan C; Koch R; Schorr SG; Wirth M
Urologe A; 2014 Oct; 53(10):1500-3. PubMed ID: 24984950
[TBL] [Abstract][Full Text] [Related]
29. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management.
Cooperberg MR; Broering JM; Latini DM; Litwin MS; Wallace KL; Carroll PR
Curr Urol Rep; 2004 Jun; 5(3):166-72. PubMed ID: 15161564
[TBL] [Abstract][Full Text] [Related]
30. Health care delivery system contributions to management of newly diagnosed prostate cancer.
Krampe N; Kaufman SR; Oerline MK; Hill D; Caram MEV; Shahinian VB; Hollenbeck BK; Maganty A
Cancer Med; 2023 Aug; 12(16):17346-17355. PubMed ID: 37475511
[TBL] [Abstract][Full Text] [Related]
31. Implications of the Merit-Based Incentive Payment System for Urology Practices.
Maganty A; Hollenbeck BK; Kaufman SR; Oerline MK; Lai LY; Caram MEV; Shahinian VB
Urology; 2022 Nov; 169():84-91. PubMed ID: 35932872
[TBL] [Abstract][Full Text] [Related]
32. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
33. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.
Ariane MM; Ploussard G; Rebillard X; Malavaud B; Rischmann P; Hennequin C; Mongiat-Artus P
World J Urol; 2015 Nov; 33(11):1741-7. PubMed ID: 25822706
[TBL] [Abstract][Full Text] [Related]
34. Association Between Private Equity Acquisition of Urology Practices and Physician Medicare Payments.
Nie J; Hsiang W; Lokeshwar SD; McMahon G; Demkowicz PC; Kenney PA; Breyer BN; Leapman MS
Urology; 2022 Sep; 167():121-127. PubMed ID: 35680053
[TBL] [Abstract][Full Text] [Related]
35. Urologists' Perceptions of Active Surveillance and Their Recommendations for Low-risk Prostate Cancer Patients.
Xu J; Bock C; Janisse J; Schwartz KL; Triest J; Cher ML; Goodman M
Urology; 2021 Sep; 155():83-90. PubMed ID: 33482128
[TBL] [Abstract][Full Text] [Related]
36. Gender Differences in Compensation, Job Satisfaction and Other Practice Patterns in Urology.
Spencer ES; Deal AM; Pruthi NR; Gonzalez CM; Kirby EW; Langston J; McKenna PH; McKibben MJ; Nielsen ME; Raynor MC; Wallen EM; Woods ME; Pruthi RS; Smith AB
J Urol; 2016 Feb; 195(2):450-5. PubMed ID: 26384452
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
J Clin Oncol; 2007 Dec; 25(34):5359-65. PubMed ID: 18048816
[TBL] [Abstract][Full Text] [Related]
38. Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists.
Kim SP; Meropol NJ; Gross CP; Tilburt JC; Konety B; Yu JB; Abouassaly R; Weight CJ; Williams SB; Shah ND
Urol Oncol; 2018 Nov; 36(11):501.e15-501.e21. PubMed ID: 30190177
[TBL] [Abstract][Full Text] [Related]
39. 2003 American Urological Association Gallup survey: physician practice patterns, cryosurgery/brachytherapy, male infertility, female urology and insurance/professional liability.
O'leary MP; Baum NH; Bohnert WW; Blizzard R; Bonney WW; Cooper TP; Dineen MK; Gee WF; Gormley EA; Ignatoff JM; Nachtsheim DA; Painter MR; Thomas R; Wei JT
J Urol; 2004 Jun; 171(6 Pt 1):2363-5. PubMed ID: 15126822
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices.
Wasson JH; Fowler FJ; Barry MJ
J Urol; 1998 Jun; 159(6):1993-6; discussion 1996-7. PubMed ID: 9598505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
